erelin (G) and triptorelin (T) for Russian health care system. METHODS: A review was conducted to collect available evidence of the clinical efficacy and safety of L in comparison with G and T. Cost-minimization analysis was performed. Direct costs of treatment with studied drugs were considered for each option: cost for 1-year hormonal therapy in a hypothetical cohort of 100 patients with PC. The calculation of costs was based on drugs' pri es from the List of Vital and Essential Drugs in Moscow region. In addition we made an estimate of the number of extra patients who could have been treated if a less expensive alternative had been applied. One-way sensitivity analysis was made. RESULTS: According to available published data LHRH agonists have similar clinical efficacy and safety that allowed us to use cost-minimization method. Costs for the medications in a hypothetical cohort of 100 patients with PC were equal to 290.263; 332.690 and 391.595 USD per year for L, G and T respectively. When L is used instead of G and T extra 14 and 34 patients can be treated with LHRH for 1 year respectively. Sensitivity analysis has shown, that L is less expensive if its price is no more than ϩ14,6 % and ϩ34,91% from baseline when compared to G and T respectively. CONCLUSIONS: L-based therapy has equal clinical efficacy comparing to the other LHRH analogues and is on average a cost saving option when compared with G and T. The incremental (non-intervention) cost was £534 (due to longer survival). CONCLUSIONS: These additional analyses from the BOLERO-2 study show that compared with PBOϩEXE, patients receiving EVEϩEXE experienced longer PFS, which translated to health gains in terms of both LYs and QALYs. EVEϩEXE was associated with savings in non-intervention costs over the initial trial period and a modest increase in nonintervention costs over the extrapolated 5-year time horizon. 
OBJECTIVES:
This study analyzed the cost-utility of everolimus ϩ exemestane (EVEϩEXE) versus placebo ϩ exemestane (PBOϩEXE) in patients with HRϩ HER2-ABC. METHODS: The phase III BOLERO-2 study randomized 724 patients with HRϩ HER2-ABC and recurrence or progression during/after nonsteroidal aromatase inhibitor therapy to EVEϩEXE or PBOϩEXE. A survival partition model was developed to compare treatment with EVEϩEXE versus PBOϩEXE (UK health care perspective). The 18-month median follow-up data on progression-free survival and mortality were obtained from BOLERO-2. Weibull functions were used to extrapolate trial data beyond the follow-up period. Utilities from published sources were combined with trial data to calculate quality-adjusted life years (QALYs) associated with health state. Background health state costs (ie, non-intervention costs) were applied to calculate incremental costs. RESULTS: At 18 months' followup, ABC patients on EVEϩEXE gained 1.33 life years (LYs) and 0.76 QALYs versus 1.27 LYs and 0.65 QALYs with PBOϩEXE. Background health state and adverse event (AE) costs were £9,944 with EVEϩEXE versus £12,924 with PBOϩEXE. Excluding drug acquisition costs, use of EVEϩEXE resulted in cost savings of £2,980. When trial data were extrapolated to 5 years, EVEϩEXE led to a gain of 3.05 LYs and 1.46 QALYs versus 2.57 LYs and 1.16 QALYs with PBOϩEXE. Background health state and AE costs were £30,094 with EVEϩEXE versus £29,560 with PBOϩEXE. The incremental (non-intervention) cost was £534 (due to longer survival). CONCLUSIONS: These additional analyses from the BOLERO-2 study show that compared with PBOϩEXE, patients receiving EVEϩEXE experienced longer PFS, which translated to health gains in terms of both LYs and QALYs. EVEϩEXE was associated with savings in non-intervention costs over the initial trial period and a modest increase in nonintervention costs over the extrapolated 5-year time horizon. 
PCN99 COST-UTILITY OF GRANULOCYTE-COLONY STIMULATING FACTORS FOR PRIMARY PROPHYLAXIS OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA IN BREAST CANCER PATIENTS IN BELGIUM

OBJECTIVES:
To assess cost-utility in Belgium of once-per-cycle primary prophylaxis (PP) with pegfilgrastim vs. no prophylaxis and vs. PP with daily granulocytecolony stimulating factors (G-CSF) filgrastim or lenograstim (11-days per label or 6-days per common clinical practice) for reducing febrile neutropenia (FN) incidence in women with primary breast cancer receiving chemotherapy carrying a 20% or higher overall risk of FN. METHODS: A decision-analytic model was constructed from a health care-payer perspective. Costs were from official Belgian list prices (April 2012) or literature and included drugs, drug administration, FN-hospitalizations and FN-related medical costs. Effectiveness inputs in terms of relative risk reduction (RRR) for FN were based on the most recently published meta-analysis (Cooper 2011). Survival and utility inputs were obtained from available data for breast cancer patients in the US (Lyman 2009) and the UK (Whyte 2011). Outcomes included number needed to treat to avoid an episode of FN (NNT), and incremental cost effectiveness ratio (ICER) in terms of cost per quality-adjusted life-years (QALY). A univariate sensitivity analysis evaluated the robustness of the model. RESULTS: Pegfilgrastim demonstrated the lowest NNT (4.69). In terms of cost-utility, pegfilgrastim was dominant vs. 11-day filgrastim or lenograstim and was considered cost-effective vs. no prophylaxis (€24,675/QALY) and 6-day filgrastim (€18,265/QALY) or lenograstim (€12,782/QALY). In a scenario analysis reducing the prices of daily G-CSFs by 30%, pegfilgrastim remained cost-effective at a willingness to pay threshold of €30,000. The sensitivity analysis revealed that most sensitive variables were effectiveness (RRR), incremental utility values (LYs and QALYs) and cost of G-CSFs, and demonstrated the overall model to be robust. CONCLUSIONS: In a Belgian setting, pegfilgrastim offered the most cost-effective approach to primary prophylaxis of FN. In the cost-utility analysis pegfilgrastim primary prophylaxis was dominant vs. 11-day G-CSF primary prophylaxis and cost-effective vs. no prophylaxis and 6-day G-CSF primary prophylaxis. 
PCN100 COST UTILITY ANALYSIS OF BORTEZOMIB IN A BIOMARKER POSITIVE SUBGROUP OF RELAPSED AND REFRACTORY FOLICULAR LYMPHOMA
OBJECTIVES:
Based on an exploratory biomarker analysis in the Phase 3 RCT LYM3001 Study that evaluated bortezomib combined with rituximab against rituximab, in a biomarker positive population of relapsed/refractory follicular lymphoma (RRFL) patients (Coiffier et al 2011, ASH), a cost-utility analysis was conducted from the UK NHS perspective. METHODS: A lifelong Markov model with monthly cycles was designed in MS Excel 2007. Three health states were defined: progression free, progression and death. Patients received active treatment for the first 5 weeks in the progression free state and best supportive care in progression. Progression free survival (PFS) probabilities were extrapolated from the randomized controlled trial. In the PSMB1 P11A C/G heterozygote and low CD68 expression subgroup of RRFL patients, the median PFS improved from 9.1 to 16.6 months (pϽ0.0001) with bortezomib/rituximab vs. rituximab alone. This subgroup was identified using laboratory tests. The total cost included the cost of drugs, administration, biomarker analysis, follow up, best supportive care, end of life care and adverse events per health state. Utilities were state dependent and disutilities were applied for adverse events. General mortality, unit costs and utilities were obtained from the literature. Annual discounting of 3.5% was applied on costs and health effects. The result measured the incremental cost (£ 2011) per quality adjusted life year (QALY) gained. RESULTS: The combination bortezomib/rituximab yielded 9.76 QALYs vs. 8.41 for rituximab alone in biomarker positive RRFL patients. The projected total costs were £ 56,362 and £37,701, respectively. The resulting incremental cost effectiveness ratio (ICER) was £13,774/QALY gained. The probabilistic sensitivity analysis indicated that the cost-effectiveness probability exceeded 55% at £20,000/QALY. CONCLUSIONS: In RRFL patients with positive biomarkers, PSMB1 P11A C/G heterozygote and low CD68 expression, bortezomib/rituximab was compared against rituximab and generated an ICER below £20,000/QALY gained. This analysis shows how personalized medicine may maximize cost-effectiveness. 
PCN101 COST EFFECTIVENESS OF EVEROLIMUS FOR SECOND LINE TREATMENT OF METASTATIC RENAL CELL CANCER IN SERBIA
OBJECTIVES:
Metastatic renal cell cancer (mRCC) is becoming an important part of Serbian health care expenditure due to its increasing incidence, inadequate prevention methods and expensive pharmaceutical options for disease control. Of all available treatment options, only sunitinib is currently reimbursed in Serbia. This study aims to assess the cost-effectiveness of everolimus in comparison to best supportive care in mRCC patients who failed to respond to treatment with sunitinib. METHODS: A Markov model was designed with respect to the Serbian treatment protocols and a health care perspective was taken. Transitions between health states were enabled by time-dependent probabilities extracted from published Kaplan-Meier curves for progression-free (PFS) and overall survival (OS). The cohorts were followed over 18 cycles, each cycle lasting 8 weeks, which covers the life-time horizon of mRCC patients. An annual discount rate of 1.5% for health and 4% for costs was applied. One-way and probabilistic sensitivity analyses (PSA) were performed to test the robustness and uncertainty around the base-case estimate. RESULTS: The incremental cost-effectiveness ratio (ICER) for everolimus was esimated at 64,028€/QALY. Sensitivity analysis identified the probabilities of OS and PFS as the main drivers of the cost-effectiveness of everolimus. The cost of everolimus and the utilities estimates were also of significant influence. PSA revealed a wide 95% confidence interval around the base-case ICER estimate (36,147 -186,053 €/QALY). Additionally, at a threshold of 14,400€/QALY (three times the GDP per capita in Serbia) everolimus did not have probability of being cost-effective. CONCLUSIONS: Base-case ICER was significantly higher than the commonly used, GDP-based threshold, recommended by WHO, indicating that everolimus would most likely be a cost-ineffective treatment in Serbian setting. However, prior to a final decision on the acceptance/rejection of everolimus, reassessment of the whole therapeutic group might be needed to constitute reasonable treatment strategies within the mRCC field. 
PCN102 THE COST OF ABSENTEEISM AND SHORT-TERM DISABILITY ASSOCIATED WITH COLORECTAL CANCER: A CASE-CONTROL STUDY
OBJECTIVES:
Examine the incremental costs of absenteeism and short-term disability associated with colorectal cancer (CRC). METHODS: The MarketScan Commercial Claims and Encounters (CCAE) and Health and Productivity Management (HPM) databases were used to identify patients age 18-64 diagnosed with CRC, with first such date identified as the index date. Patients were also required to have continuous insurance coverage and be included in the HPM database from 6 months prior through 12 months post index date. These cases were matched 1:1 without replacement based upon age, sex, and region of residence and controls
A427
were assigned an identical index date as their matched case. Absenteeism costs in the 1 year post diagnosis were then estimated using a generalized linear model with log link and variance function determined by modified Park test (GLM). Shortterm disability costs were estimated with a two part model where the first part utilized a logistic model to determine the probability of having a short-term disability claim and the second part is a GLM model for patients who had such a claim. The analyses controlled for patient characteristics, prior medical costs, and general health. RESULTS: Patients with colorectal cancer in this study (Nϭ165) were mostly male (75.76%) with a mean age of 52 years. Patients with colorectal cancer were significantly less likely to be insured via point-of-service insurance (45.45% v 79.39%; pϽ0.0001) but more likely to be insured via a preferred provider organization (44.24% v 7.88%; PϽ0.0001) compared to their healthy matches (Nϭ165). After controlling for patient characteristics, prior medical costs and general health, patients with colorectal cancer experienced, on average, $6,075 higher short-term disability costs (PϽ0.0001) and $3,633 higher absenteeism costs (PϽ0.0001) in the 1 year post diagnosis of CRC. CONCLUSIONS: Results indicate that CRC is associated with significant work-related productivity loss costs in the first year post diagnosis. 
PCN103 HOW MUCH PRICE COMPONENT IS ACCOUNTED FOR IN STATE DRUGS PURCHASE DECISIONS IN UKRAINIAN ONCOLOGY?
OBJECTIVES:
To assess the costs of drugs for treatment of oncologic diseases (using the example of hematologic malignancies) in the Ukrainian market and to explore if there is a correlation between cost per daily-defined dose (DDD) and governmental purchase decisions. METHODS: Documentary analysis (market prices and hospital purchases) was conducted, analyzing the following resources: hospital cards (to define the most frequently used drugs for treatment of hematologic malignancies and DDD), hospital drugs purchases 2011 (to define the list, quantities, and prices of drugs purchased by the state), market prices by distributors and the state registered prices (to define the median, minimum and maximum prices possible for the market). RESULTS: Drugs that were frequently used and had the minimum price per DDD were corticosteroids (dexamethazone, prednizolone), thalidomide, lomustine, chlorambucil (used for elderly patients with CLL). The correlation between the amount of packs purchased by the government and cost per DDD paid was -0.310, indicating that there is a low correlation between price increase and the state purchased decrease. Several cases when the state purchased two brand names for one generic product with extreme difference in price/mg were observed. CONCLUSIONS: State purchases in Ukraine have a tendency to include cheaper drugs in the higher amounts than more expensive ones. Though, not all of the decisions have only a price reasoning. The reasons for purchases of different brand names for one generic product should be provided.
PCN104 PROFILE OF PATIENTS AND HEALTH CARE COSTS ASSOCIATED WITH CANCER TREATMENT FROM A MEDICAL COOPERATIVE IN THE STATE OF SÃO PAULO, BRAZIL
Santos MCL, Maturana MS Unimed São José do Rio Preto, São José do Rio Preto, São Paulo, Brazil
OBJECTIVES: Due to advances in medical technology, cancer care costs are growing rapidly and expenditures with oncology treatment represents a significant burden for managed care organizations. Therefore, the study aims to evaluate the profile of oncology patients and treatment costs from UNIMED São José do Rio Preto (USJRP), a medical cooperative responsible for approximately 118,000 lives in São Paulo, Brazil. METHODS: A review of USJRP administrative claims database was conducted for patients who were under any cancer treatment between January 2011 to December 2011. Data regarding gender, age and treatment expenditures were assessed for the entire period. Only costs associated with treatment were taken into account (i.e. drugs, devices/materials and room taxes). Type of cancer was identified according to ICD-9 codes and grouped into major cancer types. Costs were reported in Brazilian Reais (1.00US$ϳ2.00BRL Jun/2012). RESULTS: A total of 324 oncology patients were identified (44.0% male and 56.0% female) with overall expenditures in the study period of BRL 4.57 million. Average age was 59.2 years (55.4 for female and 64.4 for male). Drugs accounted for 93.4% of all treatment expenditures, followed by room taxes with 4.2%. Average treatment cost per patient was BRL 14,105, being lymphoma the most expensive type of cancer (BRL 15,544 per patient). In terms of overall costs, breast cancer represented 43.8% of all treatment costs (BRL 1.98 million), followed by colorectal cancer (24.0%; BRL 1.10 million) and lung cancer (12.0%; BRL 0.55 million). CONCLUSIONS: More than 300 patients were treated for cancer in 2011 which accounted for approximately BRL 4.57million, being drugs responsible for more than 90% of all treatment expenditures. In 2011, health care costs reported for USJRP was BRL 217,849,541 (average of BRL 1,850 per life), demonstrating that costs associated with oncology treatment are high and suggesting the importance of economic evaluation of cancer drugs for the decision making process. 
CANCER -Patient-Reported Outcomes & Patient Preference Studies
PCN105 IMPACT OF PHARMACY CHANNEL ON ABANDONMENT RATE OF ORAL ONCOLYTICS
OBJECTIVES:
Oral chemotherapy agents are increasingly used for cancer treatment. The study objective was to quantify abandonment and reversal rates of oral oncolytics in patients filling prescriptions from traditional retail, Medco specialty, and other specialty pharmacies. Prescriptions are abandoned for different reasons including cost-sharing amounts and complexity of regimens prescribed. METHODS: Using a retrospective cohort design, we selected patients aged Ն18 years with a prescription for erlotinib, capecitabine, or imatinib during 2007-2011 from a Medco population of U.S. commercial and Medicare health plans. These agents represent widely available oral oncolytic agents. Patients were classified according to initial oncolytic received and pharmacy channel providing the medication. Abandonment was defined as a reversal following initial approval of prescription with no additional paid claims for the agent within 90 days of reversal. Overall reversal rates representing potential challenges filling prescriptions were also examined. Reversals occur for various reasons including incorrect information on claim or inability of patient to pay cost-sharing amount. RESULTS: Among patients treated with an oral oncolytic, 10,297 were prescribed erlotinib, 20,062 were prescribed capecitabine and 7,233 were prescribed imatinib. Mean age was 69.1, 61.3, and 62.1 years for erlotinib, capecitabine, and imatinib users, respectively. The abandonment rate of the initial oncolytic was 1.9%, 1.6%, and 1.2% for erlotinib, capecitabine, and imatinib, respectively. The rate of reversals was 4.9%, 3.7%, and 3.5% for erlotinib, capecitabine, and imatinib, respectively. For oncolytics examined, Medco specialty channel (0.2%) had lowest rates of abandonment versus other specialty (1.7% PϽ0.001) and retail (2.0% PϽ0.001). In multivariate models controlling for age, gender, and geographic region, specialty channel was significantly associated with filling the index prescription without challenges for all oncolytics. CONCLUSIONS: Low abandonment rates were observed in this study. The pharmacy channel in which patients fill their index oral oncolytic appears to be influential on patient abandonment rates. Universityhospital of Giessen and Marburg GmbH, Marburg, Hessen, Germany OBJECTIVES: High rates of compliance and persistence to medical treatments are associated with improved patient outcomes. Breast cancer survival has significantly increased, compliance with adjuvant treatment is very importance to ensure optimal treatment outcome. In this analysis, persistence i.e. the extent to which patients continue treatments was estimated for breast cancer patients on tamoxifen (TAM) and aromatase inhibitors (AI) treatment in primary care practices in Germany. METHODS: This retrospective cohort study analysed longitudinal routine care data collected by gynaecologists and general practitioners in Germany (IMS® Disease Analyzer). Non-persistence was defined as a period of Ն180 days without prescriptions. The lack of persistence was compared using Cox regression models after adjusting for age, gynecologist care, private health insurance, urban residency, practice in West-Germany, defined co-diagnoses and co-therapies (i.e. bisphosphonates). RESULTS: We included 12,412 patients diagnosed with primary breast cancer and first-time prescriptions of hormone therapy. A total of 7312 patients started with TAM (mean age 62.1 (SD: 13.5)), 5,100 with AI (anastrozole, exemestane, letrozole) (mean age 66.4 (SD: 10.6) as first line treatment. After 3 years 42.1% of TAM-patients and 40.2% of AI-patients in German practices discontinued their treatment. In the adjusted Cox model treatment in gynaecologist practice (HR: 0.46, pϽ0.001), age over 70 (HR 0.90, pϭ0 .010), change of hormone therapy substance (HR: 0.82, pϽ0.001), co-therapy with bisphosphonates (HR: 0.86, pϭ0.013) and diagnosis of diabetes mellitus (HR: 0.82, pϽ0.001) were associated with a lower risk of discontinuation of therapy. No significant effect was found for western Germany, urban residency, private insurance status and other age groups. CONCLUSIONS: Long-term persistence on hormonal treatment in women with endocrine-responsive breast cancer is low. Factors affecting treatment discontinuation need to be identified and properly addressed. Patients at high risk of nonadherence to the prescribed medication should be cared for in more individualised fashion to ensure optimal treatment outcome. OBJECTIVES: Metastatic renal cell carcinoma (mRCC) has a very high mortality rate with a 5 year survival of 5-15%. With the approval and use of a number of oral agents in the first line, treatment conditions for mRCC patients have significantly improved. Objective of this study was to evaluate the persistence in the first line treatment of mRCC patients in Germany. METHODS: The present study is based on the IMS LRx database containing 80% of all prescriptions reimbursed by the German statutory health insurance with an anonymized patient ID. The data base covers longitudinal information on patient level, such as age, gender, insurance company, region as well as prescriber specialty, date and medication on package level. Persistence was defined as the number of days from the date of the first prescription until the date of the last prescription plus the number of daily dosages prescribed. RESULTS: A total of 2799 patients starting first line treatment in mRCC between January 2010 and September 2010 were identified based on medication, co-medication and dosage. Median persistence in days was 84 for patients receiving Temsirolimus (T; nϭ384), 103 for Sorafenib (So; nϭ368), 117 for Pazopanib (P; A428
PCN106 PERSISTENCE IN PATIENTS WITH BREAST CANCER TREATED WITH TAMOXIFEN OR AROMATASE INHIBITORS: RESULTS OF A RETROSPECTIVE COHORT STUDY
PCN107 PERSISTENCE IN FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ROUTINE CARE IN GERMANY
